AG
NRIX icon

Algert Global’s Nurix Therapeutics NRIX Stock Holding History

Algert Global’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$796K Sell
51,347
-68,310
-57% -$1.13M 0.01% 902
2025
Q4 		$2.27M Sell
119,657
-444,180
-79% -$6.38M 0.04% 680
2025
Q3 		$5.21M Buy
563,837
+449,338
+392% +$4.67M 0.09% 403
2025
Q2 		$1.3M Buy
+114,499
New +$1.24M 0.03% 751
2023
Q4 		– Sell
-42,371
Closed -$333K – 1218
2023
Q3 		$333K Hold
42,371
– – 0.02% 865
2023
Q2 		$423K Buy
42,371
+2,160
+5% +$22K 0.02% 841
2023
Q1 		$357K Buy
40,211
+13,907
+53% +$145K 0.02% 902
2022
Q4 		$289K Buy
26,304
+3,710
+16% +$44.7K 0.02% 937
2022
Q3 		$294K Buy
22,594
+7,614
+51% +$121K 0.02% 952
2022
Q2 		$190K Buy
+14,980
New +$170K 0.01% 1035
2022
Q1 		– Sell
-13,053
Closed -$378K – 1269
2021
Q4 		$378K Sell
13,053
-460
-3% -$13.9K 0.05% 646
2021
Q3 		$405K Buy
+13,513
New +$417K 0.05% 632

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Algert Global's NRIX Position: Q1 2026 in Review

Algert Global reduced its Nurix Therapeutics (NRIX) stake by 57% in Q1 2026, selling an estimated $1.13M and leaving 51,347 shares worth $796K. The position accounts for 0.01% of the portfolio, ranked #902.

Algert Global first reported a position in NRIX in Q3 2021 and has held it in 12 quarters since. The position peaked at $5.21M in Q3 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Algert Global held 51,347 shares of Nurix Therapeutics worth $796K as of Q1 2026.
  • Algert Global sold 68,310 Nurix Therapeutics shares in Q1 2026, an estimated $1.13M.
  • Nurix Therapeutics made up 0.01% of Algert Global's portfolio in Q1 2026, its #902 holding.
  • Algert Global first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Algert Global's Nurix Therapeutics position peaked at $5.21M in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.